Key Highlights

  • IDEXX Laboratories shares are indicated up 3.73% in pre-market trading at $589.00, extending Monday's 1.02% after-hours gain.
  • Second-quarter revenue grew 10% as reported and 9% organically to $1,217 million, with CAG Diagnostics recurring revenue up 11% as reported.
  • EPS of $4.27 rose 18% as reported and 15% on a comparable basis, beating expectations.
  • The company narrowed full-year 2026 revenue guidance to $4,700 million to $4,745 million and raised its EPS outlook to $14.69 to $14.94.
  • IDEXX inVue Dx installed base surpassed 9,000 instruments, supported by more than 1,600 placements during the quarter.

What's Driving the Pre-Market Move

IDEXX Laboratories (NASDAQ:IDXX) shares are indicated up 3.73% in pre-market trading at $589.00, extending a 1.02% after-hours gain from Monday, after the company reported second-quarter results that beat Wall Street expectations across revenue and earnings, with shares still trading below their 52-week high of $769.98 after trimmed estimates earlier this summer.

IDEXX is a Westbrook, Maine-based global leader in veterinary diagnostics, software, and water microbiology testing, founded in 1983. The company operates through its Companion Animal Group, Water Quality Products, and Livestock, Poultry and Dairy segments, developing point-of-care diagnostic instruments, consumables, rapid assay kits, reference laboratory services, and veterinary practice management software, serving customers in more than 175 countries.

Second-quarter revenue was $1,217 million, up 10% as reported and 9% organically, driven by Companion Animal Group growth of 9%, Water revenue growth of 15% as reported, and Livestock, Poultry and Dairy revenue growth of 11% as reported. CAG Diagnostics recurring revenue, the company's core growth driver, rose 11% as reported and 10% organically, including 14% reported growth internationally and 10% growth in the U.S., outpacing broader sector growth levels.

Earnings per diluted share were $4.27, up 18% as reported and 15% on a comparable basis, supported by operating margin expansion of 140 basis points as reported to 35.0%. Gross margin improved 140 basis points as reported to 64.0%, supported by strong recurring revenue volume gains, operational productivity initiatives, and net price realization. The IDEXX inVue Dx installed base surpassed 9,000 instruments, supported by more than 1,600 placements during the quarter, while IDEXX VetLab consumables generated 15% reported revenue growth.

Guidance and Outlook

The company narrowed its full-year 2026 revenue guidance to $4,700 million to $4,745 million, reflecting reported growth of 9.1% to 10.3%, an increase of $5 million at the midpoint net of a $15 million foreign exchange headwind. Organic revenue growth guidance was raised to 8.5% to 9.7%, and CAG Diagnostics recurring revenue organic growth guidance was raised to 9.5% to 10.7%.

IDEXX also increased its full-year operating margin outlook to 32.3% to 32.5% and raised its EPS outlook to $14.69 to $14.94, an increase of $0.14 at the midpoint compared to prior guidance, reflecting an increase of 12% to 14% as reported and 13% to 15% on a comparable basis. The company will host its 2026 Investor Day on August 13, where management is expected to provide further detail on long-term strategy.

IDEXX's market capitalization stood at $44.79 billion at Monday's close, with a trailing price-to-earnings ratio of 41.81 and a forward P/E of 32.15. The stock's 52-week range spans $518.55 to $769.98, with nine of 15 analysts covering the stock rating it Buy, according to recent commentary, with a consensus target of $707 implying meaningful upside from current levels.

Conclusion

IDEXX's second-quarter beat and raised full-year guidance reflect continued strength in its core CAG Diagnostics recurring revenue business, supported by expanding instrument placements and international growth. With shares still meaningfully below their 52-week high, the durability of today's pre-market gain will likely depend on further detail expected at the company's upcoming Investor Day.

This article is for informational purposes only and does not constitute investment advice. Readers should conduct their own research before making financial decisions.